Immunomic Therapeutics dosed the first patient in its Phase 1 trial of allergy vaccine candidate ITI-9001. This is an early-stage clinical milestone that modestly de-risks development progress but provides limited near-term financial visibility.
Immunomic Therapeutics dosed the first patient in its Phase 1 trial of allergy vaccine candidate ITI-9001. This is an early-stage clinical milestone that modestly de-risks development progress but provides limited near-term financial visibility.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
